BioSpace News Archive

Reaffirming its bold ambition to become the leading dermatology company in the world, Galderma announced its intention to expand its manufacturing and innovation footprint in the Asia-Pacific region, with support from the Singapore Economic Development Board.

MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces that over 2,000 patients’ worth of new MolecuLight data will be presented at the Symposium on Advanced Wound Care Fall 2022.

Odyssey Therapeutics, Inc., a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, announced a $168 million Series B financing.

Walden Biosciences, Inc. announced that Blaine McKee, Ph.D., President and Chief Executive Officer of Walden Biosciences, will be participating in the following investor conferences during the month of October:

Pfizer Inc. and BioNTech SE announced early data from a Phase 2/3 clinical trial evaluating the safety, tolerability, and immunogenicity of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine.

SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged the first patient with [ 68 Ga]FAPI-46 at NYU Langone in its US Clinical Trial of Fibroblast Activation Protein Inhibitor (FAPI).

Abiomed, Inc . (NASDAQ: ABMD) announced that on Tuesday, November 1, 2022, the Company will release financial results for the second quarter of the fiscal year 2023.

VectivBio Holding AG today announced the pricing of an underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 2022 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held October 26 – 28, 2022, in Amsterdam, the Netherlands.

Palatin Technologies, Inc. today announced preliminary first quarter fiscal year 2023 Vyleesi® product sales results.